68.
Lim, TY, Stringfellow, EJ, Stafford, CA, DiGennaro, C, Homer, J B, Wakeland W, Eggers , SL, Kazemi R, Glos L, Ewing, EG, Bannister CB, Humphreys K, Throckmorton DC, Jalali MS. Modeling the evolution of the US opioid crisis for national policy development. Proceedings of the National Academy of Sciences of the United States of America , 119 (23), 2022; e2115714119. https://doi.org/10.1073/pnas.2115714119 NIDA. 2020, July 13. Drug misuse and addiction. https://nida.nih. gov/publications/drugs-brains-behavior-science-addiction/drug- misuse-addiction on 2023, April 24 Nawi AM, Ismail R, Ibrahim F et al. Risk and protective factors of drug abuse among adolescents: a systematic review. BMC Public Health 2021;21: 2088. do: 10.1186/s12889-021-11906-2 Arain M, Haque M, Johal L, Mathur P, Nel W, Rais A, Sandhu R, Sharma S. Maturation of the adolescent brain. Neuropsychiatric Dis Treat 2013;9: 449–461. https://doi.org/10.2147/NDT. S39776 Sprouse-Blum AS, Smith G, Sugai D, Parsa FD. Understanding endorphins and their importance in pain management. Hawaii Med J. 2010 Mar;69(3):70-1. PMID: 20397507; PMCID: PMC3104618 Dhaliwal A, Gupta M. Physiology, Opioid receptor. [Updated 2021 Jul 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. https://www.ncbi.nlm.nih.gov/books/ NBK546642/ Gottlieb M, Carlson JN, Peksa GD. Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting. Cochrane Database of Systematic Reviews 2022;5, CD013860. Accessed April 8, 2022.Doi: 10.1002/14651858.CD013860. pub2 Lehnen N, Heuser F, Sağlam M, Schulz CM, Wagner KJ, Taki M, Kochs EF, Jahn K, Brandt T, Glasauer S, Schneider E. Opioid-induced nausea involves a vestibular problem preventable by head-rest. PLoS One. 2015 Aug 27;10(8):e0135263. doi: 10.1371/journal. pone.0135263. PMID: 26313751; PMCID: PMC4551845 Gardner EL. Addiction and brain reward and antireward pathways. Adv Psychosom Med. 2011;30:22-60. doi: 10.1159/000324065. Epub 2011 Apr 19. PMID: 21508625; PMCID: PMC4549070 Olds J, & Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Compar Physiolog Psych 1954;47(6), 419–427. https://doi. org/10.1037/h0058775 Dowell D, Haegerich TM, & Chou, R. CDC Guideline for prescribing opioids for chronic pain: United States. MMWR Recommendations and Reports , 2016;65(RR-1), 1-49. http://dx.doi.org/10.15585/ mmwr.rr6501e1 American Academy of Family Physicians (AAFP). AAFP chronic pain toolkit. 2021; https://www.aafp.org/dam/AAFP/documents/ patient_care/pain_management/cpm-toolkit.pdf Centers for Disease Control and Prevention (CDC). Understanding the epidemic. 2021; https://www.cdc.gov/drugoverdose/epidemic/ index.html Stanford College of Medicine. Opioid equianalgesic table. 2022; https://palliative.stanford.edu/opioid-conversion/equivalency- table/ Cohen SP, Vase L, Hooten WM. Chronic pain: An update on burden, best practices, and new advances. The Lancet, 397 (10289), P2082-2097.2021; doi: 10.1016/S0140-6736(21)00393-7 Halpape K, Jorgenson D, Ahmed A, Kizlyk K, Landry E, Marwah R, Raiche T, & Wiebe A. Pharmacist-led strategy to address the opioid crisis: The Medication Assessment Centre Interprofessional Opioid Pain Service (MAC iOPS). Canadian Pharmacists Journal/Revue Des Pharmaciens Du Canada, 2022;155(1), 21-25. https://doi. org/10.1177/17151635211045950 Pak DJ, Yong RJ, Kaye AD, Urman RD. Chronification of pain: Mechanisms, current understanding, and clinical implications . Current Pain and Headache Reports, 22 (2), 9.2018; doi: 10.1007/s11916-018-0666-8; PMID: 29404791 American Medical Association 2021 Overdose Epidemic Report Physicians’ actions to help end the nation’s drug- related overdose and death epidemic —and what still needs to be done. 2021; https://end-overdose-epidemic.org/wp- content/uploads/2021/09/AMA-2021-Overdose-Epidemic- Report_92021.pdf U.S. Food and Drug Administration (FDA). FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: Careful medication management can reduce risks. 2022; https://www.fda.gov/drugs/ fda-drug-safety-podcasts/fda-drug-safety-podcast-fda-urges- caution-about-withholding-opioid-addiction-medications-patients Kene M, Bhopale S, Eaton A, Awsare SV, Reed ME. Opioid safety initiative associated with decreased emergency department opioid prescribing. Am J Manag Care . 2022;28(6):e203-e211. doi: 10.37765/ajmc.2022.89158 Riva JJ, Noor ST, Wang L, et al. Predictors of prolonged opioid use after initial prescription for acute musculoskeletal injuries in adults : a systematic review and meta-analysis of observational studies. Ann Intern Med . 2020;173(9):721-729. doi: 10.7326/ M19-3600 Pino CA, Wakeman SE. Prescription of opioids for acute pain in opioid naïve patients. UpToDate . Accessed April 24, 2023; https:// www.uptodate.com/contents/prescription-of-opioids-for-acute- pain-in-opioid-naive-patients U.S. Food and Drug Administration (FDA). FDA restricts prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. 2022; https://www.fda.gov/drugs/fda- drug-safety-podcasts/fda-drug-safety-podcast-fda-restricts-use- prescription-codeine-pain-and-cough-medicines-and-tramadol
91.
U.S. Drug Enforcement Agency (DEA). Drug policy. 2018; https:// www.dea.gov/drug-information/drug-policy U.S. Drug Enforcement Agency (DEA). Electronic prescriptions for controlled substances (EPCS). 2020; https://www.deadiversion. usdoj.gov/ecomm/e_rx/index.html U.S. Drug Enforcement Agency (DEA). Role of authorized agents in communicating controlled substance prescriptions to pharmacies. 2010; https://www.deadiversion.usdoj.gov/fed_regs/rules/2010/ fr1006.htm Centers for Disease Control and Prevention (CDC). Understanding the epidemic. 2021; https://www.cdc.gov/drugoverdose/epidemic/ index.html U.S. Drug Enforcement Agency (DEA). Drug policy. 2018; https:// www.dea.gov/drug-information/drug-policy U.S. Food and Drug Administration (FDA). Approved Risk Evaluation and Mitigation Strategies (REMS). 2021; https://www.accessdata. fda.gov/scripts/cder/rems/index.cfm?event=RemsDetails. page&REMS=17 American Academy of Family Physicians (AAFP). AAFP chronic pain toolkit. 2021; https://www.aafp.org/dam/AAFP/documents/ patient_care/pain_management/cpm-toolkit.pdf Centers for Disease Control and Prevention. Pocket guide: Tapering opioids for chronic pain. 2022; https://www.cdc.gov/ drugoverdose/prescribing/clinical-tools.html
118. SureScripts. Scripts Network Alliance: 2021 national progress report. Accessed April 17, 2023; https://surescripts.com/ docs/default-source/national-progress-reports/2021-national- progress-report.pdf?sfvrsn=71fcbe15_14 119. Tori ME, Larochelle MR, Naimi TS. Alcohol or benzodiazepine co- involvement with opioid overdose deaths in the United States. JAMA Network Open, 3 (4), e202361.2020; doi: 10.1001/ jamanetworkopen.2020.2361 120. U.S. Food and Drug Administration (FDA). FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: Careful medication management can reduce risks. 2022; https://www.fda.gov/drugs/ fda-drug-safety-podcasts/fda-drug-safety-podcast-fda-urges- caution-about-withholding-opioid-addiction-medications-patients 121. Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet . 2020 Jun 20;395(10241):1938- 1948. 122. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med . 2000 Oct-Nov;67(5-6):347-64. PMID: 11064485 123. NIDA. Preface. August 3. Accessed April 24, 2023; https:// nida.nih.gov/publications/principles-drug-addiction-treatment- research-based-guide-third-edition/preface 124. American College of Obstetricians and Gynecologists. Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. Obstet Gynecol. 2017;130:e81–94. 125. https://www.deadiversion.usdoj.gov/pubs/docs/MATE_Training_ Letter_Final.pdf 126. Samhsa.gov/medications-substance-use-disorders/removal-data- waiver-requirement, Accessed April 28,2023 127. Singh D, Saadabadi A. Naltrexone. StatPearls. 2022. 128. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O’Brien CP SON. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. Engl J Med. 2016;374(13):1232. 129. National Institutes of Health, HEAL Initiative®. Accessed April 11, 2023. https://heal.nih.gov/about 130. Council of State and Territorial Epidemiologists. Healthcare associated infections, drug diversion planning and response toolkit for state and local health departments, Accessed April 17, 2023, https://cdn.ymaws.com/www.cste.org/resource/resmgr/ pdfs/pdfs2/Drug_Diversion_Toolkit_LiveL.pdf 131. Maharjan S, Amjad Z, Abaza A, et al. Executive dysfunction in patients with alcohol use disorder: a systematic review. Cureus . 2022;14(9):e29207. doi: 10.7759/cureus.29207 132. Federation of State Medical Boards. Policy on physician illness and impairment: towards a model that optimizes patient safety and physician health. Accessed April 28, 2023, https://www.fsmb.org/ siteassets/advocacy/policies/policy-on-physician-impairment.pdf 133. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593. 134. Merlo, L, Teitelbaum. Substance use disorders in physicians: Epidemiology, clinical manifestations, identification, and engagement. UpToDate . Accessed April 28, 2023. 135. AMA J Ethics. 2015;888-893. doi: 10.1001/ journalofethics.2015.17.10.spec1-1510 136. Ronsley C, Nolan S, Knight R, Hayashi K, Klimas J, Walley A, Wood E, Fairbairn N. (2020). Treatment of stimulant use disorder: A systematic review of reviews. PloS One, 15(6), e0234809. https://doi.org/10.1371/journal.pone.0234809 137. Johnson BA, Ait-Daoud N, Wang XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. J AMA Psychiatry 2013; 70:1338. 138. Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med . 2021;384(2):140- 153. doi: 10.1056/NEJMoa2020214 139. Shepherd RT. Mechanism of sudden death associated with volatile substance abuse. Hum Toxicol . 1989;8(4):287-291. doi: 10.1177/096032718900800406 140. Perry, H. Inhalant misuse in children and adolescents In: Burns M, Ganetsky M, eds. UpToDate . 2023. Accessed May 10, 2023 https://www.uptodate.com 141. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med . 2008;35(2):158- 176. doi: 10.1016/j.amepre.2008.04.009 142. Pack QR, Priya A, Lagu TC, et al. Short-term safety of nicotine replacement in smokers hospitalized with coronary heart disease. J Am Heart Assoc . 2018;7(18):e009424. doi: 10.1161/ JAHA.118.009424 143. Wadgave U, Nagesh L. Nicotine replacement therapy: an overview. Int J Health Sci (Qassim) . 2016;10(3):425-435. 144. Sindelar JL. Regulating vaping—policies, possibilities, and perils. N Engl J Med . 2020;382(20):e54. doi: 10.1056/NEJMp1917065 145. Weaver MF. Prescription sedative misuse and abuse. Yale J Biol Med . 2015;88(3):247-256. 146. Hage R, Schuurmans MM. Suggested management of e-cigarette or vaping product use associated lung injury (EVALI). J Thorac Dis . 2020;12(7):3460-3468. doi: 10.21037/jtd.2020.03.101
92.
93.
69.
94.
70.
95.
71.
96.
72.
97.
73.
98.
74.
99. Kroenke K, Alford DP, Argoff C, et al. Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: A consensus panel report [published correction appears in Pain Med. 2022 Aug 31;23(9):1636]. Pain Med . 2019;20(4):724- 735. doi: 10.1093/pm/pny307. 100. U.S. Department of Health and Human Services (HHS). Indian Health Services: Pain management. 2019; https://www.ihs.gov/ painmanagement/treatmentplanning/informedconsent/ 101. Dowell D, Haegerich, TM, Chou R. DC Guideline for Prescribing Opioids for Chronic Pain: United States. MMWR Recommendations and Reports , 2016; 65 (RR-1), 1-49. doi: 10.15585/mmwr. rr6501e1 102. U.S. Department of Health and Human Services (HHS). Pain Management Best Practices Inter-Agency Task Force Report: Updates, gaps, inconsistencies, and recommendations. 2019; https://www.hhs.gov/opioids/prevention/pain-management- options/index.html 103. Centers for Disease Control and Prevention. 2022; About CDC’s opioid prescribing guideline. https://www.cdc.gov/opioids/ providers/prescribing/guideline.html 104. U.S. Food and Drug Administration (FDA). Approved Risk Evaluation and Mitigation Strategies (REMS). 2021; https://www.accessdata. fda.gov/scripts/cder/rems/index.cfm?event=RemsDetails. page&REMS=17 105. SB63. Missouri Senate modifies provisions relating to the monitoring of certain controlled substances. 2021 https://www.senate.mo.gov/21info/BTS_Web/Bill. aspx?SessionType=R&BillID=5 4228843 Accessed April 20, 2023 106. Robinson A, Wilson MN, Hayden JA, et al. Health care provider utilization of prescription monitoring programs: a systematic review and meta-analysis. Pain Med. 2021;22(7):1570-1582. doi: 10.1093/pm/pnaa412 107. SureScripts. Electronic prescribing for controlled substances: 20 years of persistence and progress. 2022; https://surescripts. com/news-center/intelligence-in-action/opioids/electronic- prescribing-for-controlled-substances-20-years-of-persistence- and-progress, 2022. 108. SureScripts. Scripts Network Alliance: 2021 national progress report. 2022; https://surescripts.com/docs/default-source/ national-progress-reports/2021-national-progress-report. pdf?sfvrsn=71fcbe15_14 109. National Conference of State Legislatures (NCSL). Prescribing policies: States confront opioid overdose epidemic. 2019; https://www.ncsl.org/research/health/prescribing-policies-states- confront-opioid-overdose-epidemic.aspx 110. U.S. Drug Enforcement Agency (DEA). Drugs of abuse: A DEA resource guide. https://www.dea.gov/sites/default/files/2020-04/ Drugs%20of%20Abuse%202020-Web%20Version-508%20 compliant-4-24-20_0.pdf 111. Alternatives to Opiates (ALTOSM) Program. Accessed April 1, 2023; https://stjosephsalto.org/about. 112. Moradi MM, Moradi MM, Safaie A, Baratloo A, Payandemehr P. Sub dissociative dose of ketamine with haloperidol versus fentanyl on pain reduction in patients with acute pain in the emergency department; a randomized clinical trial. Am J Emerg Med. 2022 Apr;54:165-171. doi: 10.1016/j.ajem.2022.02.012; PMID: 35152127 113. Levine DA. “Pharming”: the abuse of prescription and over- the-counter drugs in teens. Current opinion in pediatrics. 2007;19(3):270-274. 114. Food and Drug Administration. Disposal of unused medicines: what you should know. Accessed April 15, 2023; https://www.fda. gov/drugs/safe-disposal-medicines/disposal-unused-medicines- what-you-should-know 115. U.S. Food and Drug Administration (FDA). FDA education blueprint for health care providers involved in treating and monitoring patients with pain. 2018 116. U.S. Food and Drug Administration (FDA). FDA warns about several safety issues with opioid pain medicines; requires label changes. Accessed April 9, 2023; https://www.fda.gov/drugs/fda- drug-safety-podcasts/fda-drug-safety-podcast-fda-warns-about- several-safety-issues-opioid-pain-medicines-requires-label 117. U.S. Food and Drug Administration (FDA). Approved Risk Evaluation and Mitigation Strategies (REMS). Accessed April 16, 2021; https://www.accessdata.fda.gov/scripts/cder/rems/index. cfm?event=RemsDetails.page&REMS=17
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
76
Powered by FlippingBook